NCT03244059View on ClinicalTrials.gov

Belimumab Treatment of Emphysema Patients With Anti-GRP78 Autoantibodies

PHASE2CompletedINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

August 9, 2018

Primary Completion Date

April 1, 2022

Study Completion Date

April 1, 2022

Conditions
Chronic Obstructive Pulmonary DiseaseEmphysema
Interventions
BIOLOGICAL

Belimumab

Belimumab is an anti-BLyS (B-lymphocyte stimulating factor) agent administered by infusion.

DRUG

Placebo

An identically appearing placebo infusion.

Trial Locations (1)

35205

UAB Lung Health Center, Birmingham

Sponsors

Collaborators (1)

GlaxoSmithKline
All Listed Sponsors
collaborator

GlaxoSmithKline

INDUSTRY

lead

University of Alabama at Birmingham

OTHER

NCT03244059 - Belimumab Treatment of Emphysema Patients With Anti-GRP78 Autoantibodies | Biotech Hunter | Biotech Hunter